Hetero Labs Limited
Records under this name other than the patents Hetero Labs Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 12 patents it holds.
Showing 1 to 6 of 6 · Back to Hetero Labs Limited
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,669,305 | C-3 novel triterpenone with C-28 urea derivatives as HIV inhibitors Lapsed on the fee record Ended Jun 2, 2024 · USPTO record | Lapsed on the fee record | Ended Jun 2, 2024 | USPTO record |
| US 10,370,405 | C-3 novel triterpenone with C-28 amide derivatives as HIV inhibitors Lapsed on the fee record Ended Aug 6, 2023 · USPTO record | Lapsed on the fee record | Ended Aug 6, 2023 | USPTO record |
| US 9,868,758 | Betulinic proline imidazole derivatives as HIV inhibitors Lapsed on the fee record Ended Jan 16, 2022 · USPTO record | Lapsed on the fee record | Ended Jan 16, 2022 | USPTO record |
| US 9,637,516 | Betulinic acid proline derivatives as HIV inhibitors Lapsed on the fee record Ended May 2, 2021 · USPTO record | Lapsed on the fee record | Ended May 2, 2021 | USPTO record |
| US 9,067,966 | Lupeol-type triterpene derivatives as antivirals Lapsed on the fee record Ended Jun 30, 2019 · USPTO record | Lapsed on the fee record | Ended Jun 30, 2019 | USPTO record |
| US 8,802,727 | Pharmaceutically acceptable salts of betulinic acid derivatives Lapsed on the fee record Ended Aug 12, 2018 · USPTO record | Lapsed on the fee record | Ended Aug 12, 2018 | USPTO record |